S&P 500   4,281.61 (+0.33%)
DOW   33,755.45 (+0.27%)
QQQ   351.73 (+0.83%)
AAPL   178.69 (+0.49%)
MSFT   325.73 (+0.73%)
META   264.95 (+0.51%)
GOOGL   122.42 (-0.07%)
AMZN   125.12 (+3.21%)
TSLA   230.33 (+2.56%)
NVDA   382.36 (+2.03%)
NIO   7.67 (-1.16%)
BABA   86.46 (+1.38%)
AMD   119.98 (+1.82%)
T   15.96 (-0.87%)
F   13.59 (+0.00%)
MU   64.32 (-4.09%)
CGC   0.71 (-1.91%)
GE   106.45 (+0.35%)
DIS   91.94 (-0.63%)
AMC   4.59 (-2.96%)
PFE   39.12 (+0.59%)
PYPL   64.68 (+1.00%)
NFLX   404.80 (+1.26%)
S&P 500   4,281.61 (+0.33%)
DOW   33,755.45 (+0.27%)
QQQ   351.73 (+0.83%)
AAPL   178.69 (+0.49%)
MSFT   325.73 (+0.73%)
META   264.95 (+0.51%)
GOOGL   122.42 (-0.07%)
AMZN   125.12 (+3.21%)
TSLA   230.33 (+2.56%)
NVDA   382.36 (+2.03%)
NIO   7.67 (-1.16%)
BABA   86.46 (+1.38%)
AMD   119.98 (+1.82%)
T   15.96 (-0.87%)
F   13.59 (+0.00%)
MU   64.32 (-4.09%)
CGC   0.71 (-1.91%)
GE   106.45 (+0.35%)
DIS   91.94 (-0.63%)
AMC   4.59 (-2.96%)
PFE   39.12 (+0.59%)
PYPL   64.68 (+1.00%)
NFLX   404.80 (+1.26%)
S&P 500   4,281.61 (+0.33%)
DOW   33,755.45 (+0.27%)
QQQ   351.73 (+0.83%)
AAPL   178.69 (+0.49%)
MSFT   325.73 (+0.73%)
META   264.95 (+0.51%)
GOOGL   122.42 (-0.07%)
AMZN   125.12 (+3.21%)
TSLA   230.33 (+2.56%)
NVDA   382.36 (+2.03%)
NIO   7.67 (-1.16%)
BABA   86.46 (+1.38%)
AMD   119.98 (+1.82%)
T   15.96 (-0.87%)
F   13.59 (+0.00%)
MU   64.32 (-4.09%)
CGC   0.71 (-1.91%)
GE   106.45 (+0.35%)
DIS   91.94 (-0.63%)
AMC   4.59 (-2.96%)
PFE   39.12 (+0.59%)
PYPL   64.68 (+1.00%)
NFLX   404.80 (+1.26%)
S&P 500   4,281.61 (+0.33%)
DOW   33,755.45 (+0.27%)
QQQ   351.73 (+0.83%)
AAPL   178.69 (+0.49%)
MSFT   325.73 (+0.73%)
META   264.95 (+0.51%)
GOOGL   122.42 (-0.07%)
AMZN   125.12 (+3.21%)
TSLA   230.33 (+2.56%)
NVDA   382.36 (+2.03%)
NIO   7.67 (-1.16%)
BABA   86.46 (+1.38%)
AMD   119.98 (+1.82%)
T   15.96 (-0.87%)
F   13.59 (+0.00%)
MU   64.32 (-4.09%)
CGC   0.71 (-1.91%)
GE   106.45 (+0.35%)
DIS   91.94 (-0.63%)
AMC   4.59 (-2.96%)
PFE   39.12 (+0.59%)
PYPL   64.68 (+1.00%)
NFLX   404.80 (+1.26%)
NASDAQ:BIOL

BIOLASE (BIOL) Stock Forecast, Price & News

$0.08
0.00 (-3.72%)
(As of 10:50 AM ET)
Compare
Today's Range
$0.07
$0.08
50-Day Range
$0.08
$0.34
52-Week Range
$0.06
$5.94
Volume
1.63 million shs
Average Volume
2.49 million shs
Market Capitalization
$2.35 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.63

BIOLASE MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
7,111.5% Upside
$5.63 Price Target
Short Interest
Healthy
3.69% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.18mentions of BIOLASE in the last 14 days
Based on 5 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.90 out of 5 stars


BIOL stock logo

About BIOLASE (NASDAQ:BIOL) Stock

BIOLASE, Inc. is a medical device company, which engages in the developing, manufacturing, marketing and sale of laser systems in dentistry and medicine. It operates through the Waterlase (all-tissue) systems, and Diode (soft-tissue) systems products. The Waterlase systems use a patented combination of water and laser energy to perform procedures using drills, scalpels, and other traditional dental instruments for cutting soft and hard tissue. The Diode systems perform soft tissue, pain therapy, and cosmetic procedures, including teeth whitening. The company was founded in 1987 and is headquartered in Lake Forest, CA.

Receive BIOL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BIOLASE and its competitors with MarketBeat's FREE daily newsletter.

BIOL Stock News Headlines

Maxim Group Sticks to Their Buy Rating for Biolase (BIOL)
Graphite Shortage Could Derail the $7 Trillion EV Transition
Graphite (not lithium) is expected to see the largest increase in demand of all battery metals over the next decade. But projections warn of an 8 million ton shortfall of graphite by 2040. That's why 97 more graphite mines are needed just to keep up with battery production for the $7 trillion transition to electric vehicles.
Biolase to Cut 20% of Workforce
BIOLASE (NASDAQ:BIOL) Coverage Initiated at StockNews.com
Graphite Shortage Could Derail the $7 Trillion EV Transition
Graphite (not lithium) is expected to see the largest increase in demand of all battery metals over the next decade. But projections warn of an 8 million ton shortfall of graphite by 2040. That's why 97 more graphite mines are needed just to keep up with battery production for the $7 trillion transition to electric vehicles.
Earnings Outlook For Biolase
Biolase earnings: here's what Wall Street expects
StockNews.com Initiates Coverage on BIOLASE (NASDAQ:BIOL)
See More Headlines

BIOL Price History

BIOL Company Calendar

Last Earnings
3/28/2023
Today
6/08/2023
Next Earnings (Estimated)
8/10/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Dental equipment & supplies
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:BIOL
Previous Symbol
NASDAQ:BLTI
Employees
158
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$5.63
High Stock Price Forecast
$14.00
Low Stock Price Forecast
$1.50
Forecasted Upside/Downside
+7,111.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-28,630,000.00
Pretax Margin
-60.73%

Debt

Sales & Book Value

Annual Sales
$48.46 million
Book Value
$0.63 per share

Miscellaneous

Free Float
31,139,000
Market Cap
$2.44 million
Optionable
Not Optionable
Beta
1.37

Key Executives

  • John R. Beaver
    President, Chief Executive Officer & Director
  • Steven Sandor
    Chief Operating Officer
  • Jennifer Brighton
    Chief Financial Officer
  • Russell Morrow
    Chief Dental Officer
  • William E. Brown
    Vice President-Innovation & Business Development













BIOL Stock - Frequently Asked Questions

Should I buy or sell BIOLASE stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for BIOLASE in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" BIOL shares.
View BIOL analyst ratings
or view top-rated stocks.

What is BIOLASE's stock price forecast for 2023?

2 brokerages have issued twelve-month price objectives for BIOLASE's stock. Their BIOL share price forecasts range from $1.50 to $14.00. On average, they predict the company's stock price to reach $5.63 in the next twelve months. This suggests a possible upside of 7,111.5% from the stock's current price.
View analysts price targets for BIOL
or view top-rated stocks among Wall Street analysts.

How have BIOL shares performed in 2023?

BIOLASE's stock was trading at $0.65 at the start of the year. Since then, BIOL stock has decreased by 88.0% and is now trading at $0.0780.
View the best growth stocks for 2023 here
.

When is BIOLASE's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023.
View our BIOL earnings forecast
.

How were BIOLASE's earnings last quarter?

BIOLASE, Inc. (NASDAQ:BIOL) posted its quarterly earnings data on Tuesday, March, 28th. The medical technology company reported ($1.28) earnings per share for the quarter. The medical technology company had revenue of $14.05 million for the quarter. BIOLASE had a negative net margin of 60.92% and a negative trailing twelve-month return on equity of 244.91%.

When did BIOLASE's stock split?

BIOLASE's stock reverse split on the morning of Friday, April 29th 2022. The 1-25 reverse split was announced on Friday, April 29th 2022. The number of shares owned by shareholders was adjusted after the market closes on Friday, April 29th 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

What guidance has BIOLASE issued on next quarter's earnings?

BIOLASE updated its FY 2023 earnings guidance on Friday, May, 26th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $60.58M-, compared to the consensus revenue estimate of $59.91 million.

What is John R. Beaver's approval rating as BIOLASE's CEO?

4 employees have rated BIOLASE Chief Executive Officer John R. Beaver on Glassdoor.com. John R. Beaver has an approval rating of 13% among the company's employees. This puts John R. Beaver in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. 35.0% of employees surveyed would recommend working at BIOLASE to a friend.

What other stocks do shareholders of BIOLASE own?
What is BIOLASE's stock symbol?

BIOLASE trades on the NASDAQ under the ticker symbol "BIOL."

Who are BIOLASE's major shareholders?

BIOLASE's stock is owned by many different institutional and retail investors. Top institutional investors include Perkins Capital Management Inc. (10.34%) and Renaissance Technologies LLC (0.53%). Insiders that own company stock include Education Foundation Schuler, John R Beaver, John R Beaver, Jonathan T Md Lord and Larry N Feinberg.
View institutional ownership trends
.

How do I buy shares of BIOLASE?

Shares of BIOL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is BIOLASE's stock price today?

One share of BIOL stock can currently be purchased for approximately $0.08.

How much money does BIOLASE make?

BIOLASE (NASDAQ:BIOL) has a market capitalization of $2.44 million and generates $48.46 million in revenue each year. The medical technology company earns $-28,630,000.00 in net income (profit) each year or ($3.47) on an earnings per share basis.

How many employees does BIOLASE have?

The company employs 158 workers across the globe.

How can I contact BIOLASE?

BIOLASE's mailing address is 27042 Towne Center Drive Suite 270, Lake Forest CA, 92610. The official website for the company is www.biolase.com. The medical technology company can be reached via phone at (949) 361-1200, via email at rcaron@dresnerallencaron.com, or via fax at 949-273-6677.

This page (NASDAQ:BIOL) was last updated on 6/8/2023 by MarketBeat.com Staff

My Account -